

Date: 9th August, 2019

To,
Listing Department,
BSE Limited
Floor 25, PJ Tower
Dalal Street,
Mumbai – 400 001

Script Code: 540359

Sub.: Outcome of the proceedings of the meeting of the Board of Directors of the Company

Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 9th August, 2019, inter—alia, considered and approved the Unaudited Financial Results for quarter ended 30th June, 2019. The same has also been reviewed by the Audit Committee in its meeting held today.

A copy of the Statement of Unaudited Financial Results for the quarter ended 30th June, 2019, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 11:00 am and concluded 4:30 pm.

We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter ended 30th June, 2019 and Board has also taken on record their Limited Review Report on said Results.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited



Yash J. Vora
Company Secretary



Statement of Standalone Unaudited Results for the Quarter ended 30.06.2019


(in Rs.)					
Sr. No.	Particulars	Quarter Ended (30.06.2019)	Preceding Quarter ended (31.03.19)	Corresponding Quarter Ended (30.06.2018)	Previous year ended (31.03.2019)
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Income from Operations				
	(a) Revenue from operations	41134972	32261325	33827442	120126358
	(b) Other income	187266	327820	42594	481988
	Total income from operations (net) (a+b)	41322238	32589145	33870036	120608346
2	Expenses				
	(a) Cost of materials consumed	18841449	1958588	15243666	39233109
	(b) Purchase of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	4054194	-2335568	2712514	12174762
	(d) Employee benefits expense	7015749	5283443	4904966	20754610
	(e) Finance Costs	148700	-48222	65114	325496
	(f) Depreciation and amortisation expense	2168263	2559484	2552100	10302507
	(g) Other expenses*	11948511	16345164	7777540	36836606
	Total expenses	44176866	23762889	33255900	119627090
3	Profit/(Loss) from operations before exceptional items and tax (1-2)	-2854628	8826256	614136	981256
4	Exceptional Items	-	-	-	-
5	Profit/ (Loss) before tax (3-4)	-2854628	8826256	614136	981256
6	Tax expense:				
	(1) Current tax	-	750,000.00	-	750000
	(2) Deferred tax	-	(555,741)	-	(555,741)
7	Net Profit / (Loss) for the period from continuing operations (5-6)	-2854628	8631997	614136	786997
8	Profit/(loss) from discontinuing operations	-	-	-	-
9	Tax expense of discontinuing operations	-	-	-	-
10	Profit/(loss) from Discontinuing operations (after tax) (8-9)	-	-	-	-
11	Profit (Loss) for the period (7+10)	-2854628	8631997	614136	786997
12	Other Comprehensive Income	-	-	-	-
13	Total Comprehensive Income for the period (11+12) Comprising Profit (Loss) and Other comprehensive Income for the period)	-2854628	8631997	614136	786997
14	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000
15	Earnings per share (for continuing operation) (of Rs. 10/- each) (not annualised):				
	(a) Basic	-0.76	2.31	0.16	0.21
	(b) Diluted	-	-	-	-



Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 9th August, 2019
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter ended 30th June, 2019
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter ended 30th June, 2019 in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED



Alkesh Gosalia
Managing Director
(Finance and Operations)

Place: Hadamtala (Rajkot)

Date: 09.08.2019

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. A.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and three months ended 30th June 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on 9th August 2019. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. A.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. A.C.A. DISA
(Information Systems Audit)
M. No. 144246

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 09.08.2019



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

Zarna M Shah

ZARNA M SHAH
Partner
M. No. 144246
UDIN: 19144246AAAAAB6392

Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261

(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com